Changing
Vor Bio’s $4B+ Revival Deal for RemeGen’s Autoimmune Drug Triggers Divergent Stock Moves
Vor Bio; RemeGen; telitacicept; autoimmune disease; $4 billion deal; myasthenia gravis; stock reaction; CEO change; PIPE financing
FDA’s Top Cell and Gene Therapy Leaders Exit Amid CBER Upheaval
FDA; cell therapy; gene therapy; CBER; Nicole Verdun; Rachael Anatol; Peter Marks; leadership changes; biopharma regulation
ASCO25 Primer: Navigating Cancer R&D Amid Regulatory Uncertainty
ASCO25; cancer research; oncology; regulatory uncertainty; immunotherapy; precision medicine; diagnostics; expert perspectives; policy changes
CMS would absorb 340B drug discount program under leaked HHS reorganization proposal
340B, Centers for Medicare and Medicaid Services, HHS, reorganization, Programs – Publication Format, proposal – intent, drug discount program, United States Health Resources and Services Administration, CMS, Policy, Leaked, Changing
New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities
United States National Institutes of Health, recipients, NIH, Policy, Diversity, Changing, Condition, civil, federal, civil, protections, recipients, Israeli (population group), Civil Rights Act, 1964
Immunovant Refines R&D Strategy with New Leadership
Immunovant, Roivant, R&D Focus, Leadership Changes, IMVT-1402
Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg
United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible
Biopharma Layoff Trends in Q1 2025 and Outlook for Q2
Biopharma layoffs, Q1 2025 layoffs, biotech job cuts, pharma workforce reductions, restructuring, patent cliffs, regulatory challenges, Q2 layoff forecast, pharmaceutical employment trends, biopharma industry changes.
Mass Firings at FDA Spark Concerns Over Agency’s Future
FDA, layoffs, leadership changes, public health, drug regulation, Trump administration
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash